Corvus Pharma Q1 2024 GAAP EPS $(0.12), Inline
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/18/2023 | $7.00 | Outperform | Oppenheimer |
| 12/3/2021 | $5.00 → $8.00 | Overweight | Cantor Fitzgerald |
| 12/1/2021 | $8.00 | Buy | Jefferies |
| 8/3/2021 | $4.00 → $3.50 | Neutral | Mizuho |
| 7/16/2021 | $9.50 → $6.00 | Buy | HC Wainwright & Co. |
BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. "Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases. The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus will be to lead the development of CPI-818, the Company's ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases. CPI-818 is currently being studied in a Phase 1/1b clinical trial for the treatment of T cell lymphomas, the results of which we believe could support advancing CPI-818 into a global Phase 2 trial. In addition, recent resea
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 to $8.
BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. Abou
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. About Cor
10-Q - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, to prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. "We continue to build evidence that selective ITK inhibition can
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2024. "
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Aram Lyu, Ph.D., a postdoctoral fellow at Fred Hutch Cancer Center, University of California, San Francisco and Parker Scholar at the Parker Institute for Cancer Immunotherapy. Dr. Lyu'
SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00
Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously
Jefferies resumed coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $8.00
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)